High-flux hemodialysis (which removes large toxins) reduces the risk of premature death in many patients with chronic kidney disease (CKD), according to a new study. The results suggest that this ...

Purpose. The feasibility of using a limitedsampling algorithm for administration of vancomycin for treatment of vascular-access-related bacteremia in outpatient high flux hemodialysis was investigated ...

Please provide your email address to receive an email when new articles are posted on . Hemodiafiltration may allow more effective toxin removal vs. high-flux hemodialysis. Hemodiafiltration was ...

Please provide your email address to receive an email when new articles are posted on . A study of patients from eight European countries showed lower mortality when using high-dose hemodiafiltration ...

A secondary analysis of data from the Hemodialysis (HEMO) Study has enhanced our comprehension of the risk factors for cerebrovascular mortality in maintenance hemodialysis patients, and has ...

High-flux hemodialysis (which removes large toxins) reduces the risk of premature death in many patients with chronic kidney disease (CKD), according to a study appearing in the March 2009 issue of ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx ...

Among patients with a history of cardiovascular disease or diabetes, all-cause mortality was comparable between the treatments. High-dose hemodiafiltration results in a 23% lower risk of death than ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window High-dose ...

High-flux biocompatible synthetic dialyser membranes and ultrapure dialysate might improve the quality and effectiveness of haemodialysis. However, a recent randomized controlled trial showed no ...

Baxter International says it's achieved a 25% lower mortality risk for up to four years in hemodialysis patients in a study of its new therapy. In a 48-month study of 1,092 dialysis patients, Baxter's ...